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5. Report 
5.1 Proposed Executive Summary 
DENV causes significantly more human disease than any other abovirus. Annually, an 
estimated of 50-100 million cases of severe dengue require hospitalization in which 500,000 
resulted in DHF/DSS, with more than 20,000 death worldwide (WHO DengueNet report, 
2005). Hence, it has now been recognized as a major expanding public health problem of the 
country. Dengue viruses cause a spectrum of illness ranging from asymptomatic infection or 
mild febrile illness to severe and fatal hemorrhagic disease. While majority experience 
uncomplicated Dengue Fever (DF), Dengue Hemorrhagic Fever (DHF) can present with 
severe clinical manifestations including transient vascular permeability resulting in plasma 
leakage (WHO, 1997). No specific treatment is available to date. 
Previous studies suggested the involvement of the events in the peripheral blood in association 
with the DENV disease severity, such as dengue viral replication, cytokine expression, and 
cellular activation / proliferation and robust host inflammatory immune response (Rothman, 
2004). Antibody-dependent enhancement of viral replication is the most widely accepted 
explanation for the association between DHF and pre-existing antibody. However, it remains 
considerable uncertainty as to how virus-host interaction triggers the inflammatory response 
resulting in plasma leakage, the hallmark of DHF/DSS. 
FcGRII has been reported to play a role in pathogenesis of severe dengue infections (Loke et 
al., 2002; Littaua et al., 1990). It functions to mediate antibody enhancement in vitro by 
binding to virus-IgG complexes. A fundamental to any discussion of DENV pathogenesis is 
the association of secondary infection with heterologous serotypes with DHF/DSS. Antibody 
Dependent Enhancement (ADE) model during secondary infections, postulates that DENV 
specific antibodies either cross reactive antibodies, can interact with DENV without 
neutralizing the virus, and thereby requires FcG receptors to mediate entry of antibody coated 
DENV into cells (Clyde et al., 2006; Coffey et al, 2009). 
Therefore, this proposed study investigated and to characterized the CNV of FcGRII gene 
among the DF and DHF patients. Though association of FcGRII gene SNP polymorphism 
with dengue has been reported earlier (Loke et al, 2002), none investigated the copy number 
of this gene and its association to the susceptibility of plasma leakage. 
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5.3 Introduction 
Dengue viruses cause a spectrum of illness ranging from asymptomatic infection or mild 
febrile illness to severe and fatal hemorrhagic disease. While majority experience 
uncomplicated Dengue Fever (DF), Dengue Hemorrhagic Fever (DHF) can present with 
severe clinical manifestations including occurrence of vascular permeability defect resulting in 
plasma leakage, multifactorial haemostatic abnormalities (WHO, 1997). No specific treatment 
is available to date. 
DENV causes significantly more human disease than any other abovirus. Annually, an 
estimated of 50-100 million cases of severe dengue require hospitalization of which 500,000 
resulted in DHF/DSS, and more than 20,000 death worldwide. It has been documented that 
DENV is endemic in more than 100 countries, including most of the Southeast Asia, South 
and Central America, the Carribean and South Pacific regions, and DHF/DSS in more than 60 
countries (WHO DengueNet report, 2005). 
Previous studies suggested the involvement of the events in the peripheral blood in association 
with the DENV disease severity and outcome, such as dengue viral replication, cytokine 
expression, and cellular activation / proliferation (Rothman, 2004). Severe form of dengue 
infection has also been associated with robust host inflammatory immune response. Antibody-
dependent enhancement of viral replication is the most widely accepted explanation for the 
association between DHF and pre-existing antibody. However, it remains considerable 
uncertainty as to how the virus-host interaction triggers the inflammatory response resulting in 
plasma leakage, the hallmark of DHF/DSS. 
FcG receptor genes had been reported to play a role in antibody dependent enhancement 
(Kontny et al., 1988; Nielsen, 2009). One of the subclass of the FcGR gene cluster namely 
FcGR3B was suggested to mediate phagocytosis (Flesch et al., 1997) and uptake of immune 
complexes (Fanciulli et al., 2008; Wilcocks et al., 2008). Recent studies have associated this 
gene with a number of autoimmune diseases (reviewed by Fanciulli, 2007). To date no study 
was done on FcGR3B with dengue. A fundamental to any discussion of DENV pathogenesis 
is the association of secondary infection with heterologous serotypes with DHF/DSS. This has 
been evidenced by numerous studies that secondary infection is an important risk factor for 
severe disease, although there are occationally exceptional cases. Antibody Dependent 
Enhancement (ADE) model, postulates that some DENV specific antibodies either cross 
reactive antibodies, can interact with DENV without neutralizing the virus, and thereby 
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